Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sterling Biotech:...

    Sterling Biotech: Accused in Rs 8100 crore loan fraud held in Albania

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-23T10:05:53+05:30  |  Updated On 23 March 2019 10:05 AM IST
    Sterling Biotech: Accused in Rs 8100 crore loan fraud held in Albania


    The ED had ensued a red corner notice against him from the Interpol on March 11. The detention has happened based on this warrant, the officials said.


    New Delhi: Hitesh Patel, an accused in the Rs 8,100-crore bank loan fraud allegedly perpetrated by Gujarat-based Sterling Biotech group, has been detained in Albania on the basis of an Interpol notice issued against him by the ED, officials said Friday. Hitesh Narender Bhai Patel was apprehended by law enforcement officials of that country from the capital city of Tirana on March 20, they said.



    The officials later informed Indian investigative agencies about the development and the Enforcement Directorate officials are expected to reach Albania soon to secure his extradition.

    "Patel is an accused in the case and is the brother-in-law of one of the main accused, Chetan Sandesara. The other prime accused is Nitin Sandesara. Patel is expected to be extradited to India soon," they said.

    The ED had ensued a red corner notice against him from the Interpol on March 11. The detention has happened based on this warrant, the officials said.


    Also Read: Banks agree to one time settlement with Sterling Biotech with 65 percent haircut



    The agency said Patel was instrumental in getting dummy directors for shell companies used by Sandesaras.The Sandesara brothers are also stated to be in Albania and on March 19, a Delhi court had allowed the ED to send extradition requests to that country against the two.

    The ED had told the court that as per reliable sources, the accused -- Nitin Jayantilal Sandesara and Chetankumar Jayantilal Sandesara, both directors of Sterling Biotech Ltd (SBL) -- have obtained the citizenship of Albania and non-bailable warrants (NBW) were issued against them earlier this year.

    SBL is headquartered in Gujarat's Vadodara.

    The agency claimed that Patel "also handled and managed illicit cash transactions for Sandesaras and acted as director in many companies and siphoned off loan funds for purchasing luxury cars".

    The agency had earlier summoned him in the case, but he was absconded from the country, the officials said.


    Also Read: Extradition process against 4 Sterling Biotech promoters initiated: ED tells court



    A court issued NBW is already pending against him, they said.

    The ED has also sought to tag the Sandesara brothers, Chetan Sandesara's wife Dipti and Patel under the Fugitive Economic Offenders Act and had moved a court in Delhi to confiscate all their assets.

    The ED and the Central Bureau of Investigation have booked the company, its directors -- Sandesara brothers, Dipti Chetan Sandesara, Rajbhushan Omprakash Dixit, Vilas Joshi, chartered accountant Hemant Hathi, former director Andhra Bank Anup Garg and some unidentified persons in connection with the alleged bank fraud case.

    It is alleged that the company took loans of over Rs 5,000 crore from a consortium led by Andhra Bank, which had turned into non-performing assets. The total volume of the alleged loan defraud is pegged at Rs 8,100 crore.

    The agency has filed five charge sheets in this case till now and attached properties valued at Rs 4,710 crore.

    The ED, in this case, had said it is investigating the role of "public officials" for suspected bribery of about Rs 140 crore.

    The accused are also being probed by the ED for allegedly bribing senior Income Tax department officials as part of an earlier criminal complaint.


    Also Read: Rs 8100 crore bank loan fraud case: Sterling Biotech receives non bailable warrants





    AlbaniaallegedlyEDEnforcement DirectorateFixed exchange-rate systemfraudgujarat pharmaHitesh Narender Bhai PatelLatest NewsNew Delhipharmapharma newspharma news indiaPharmaceutical industryPMLAPrevention of Money Laundering ActRCNRed Corner NoticeSBLSBL latestSBL promotersSterling BiotechSterling Biotech LtdTirana
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok